View Item 

Show simple item record

A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

dc.contributor.authorLee, Alice W.
dc.contributor.authorBomkamp, Ashley
dc.contributor.authorBandera, Elisa V.
dc.contributor.authorJensen, Allan
dc.contributor.authorRamus, Susan J.
dc.contributor.authorGoodman, Marc T.
dc.contributor.authorRossing, Mary Anne
dc.contributor.authorModugno, Francesmary
dc.contributor.authorMoysich, Kirsten B.
dc.contributor.authorChang‐claude, Jenny
dc.contributor.authorRudolph, Anja
dc.contributor.authorGentry‐maharaj, Aleksandra
dc.contributor.authorTerry, Kathryn L.
dc.contributor.authorGayther, Simon A.
dc.contributor.authorCramer, Daniel W.
dc.contributor.authorDoherty, Jennifer A.
dc.contributor.authorSchildkraut, Joellen M.
dc.contributor.authorKjaer, Susanne K.
dc.contributor.authorNess, Roberta B.
dc.contributor.authorMenon, Usha
dc.contributor.authorBerchuck, Andrew
dc.contributor.authorMukherjee, Bhramar
dc.contributor.authorRoman, Lynda
dc.contributor.authorPharoah, Paul D.
dc.contributor.authorChenevix‐trench, Georgia
dc.contributor.authorOlson, Sara
dc.contributor.authorHogdall, Estrid
dc.contributor.authorWu, Anna H.
dc.contributor.authorPike, Malcolm C.
dc.contributor.authorStram, Daniel O.
dc.contributor.authorPearce, Celeste Leigh
dc.date.accessioned2016-11-18T21:22:52Z
dc.date.available2018-02-01T14:56:11Zen
dc.date.issued2016-12-15
dc.identifier.citationLee, Alice W.; Bomkamp, Ashley; Bandera, Elisa V.; Jensen, Allan; Ramus, Susan J.; Goodman, Marc T.; Rossing, Mary Anne; Modugno, Francesmary; Moysich, Kirsten B.; Chang‐claude, Jenny ; Rudolph, Anja; Gentry‐maharaj, Aleksandra ; Terry, Kathryn L.; Gayther, Simon A.; Cramer, Daniel W.; Doherty, Jennifer A.; Schildkraut, Joellen M.; Kjaer, Susanne K.; Ness, Roberta B.; Menon, Usha; Berchuck, Andrew; Mukherjee, Bhramar; Roman, Lynda; Pharoah, Paul D.; Chenevix‐trench, Georgia ; Olson, Sara; Hogdall, Estrid; Wu, Anna H.; Pike, Malcolm C.; Stram, Daniel O.; Pearce, Celeste Leigh (2016). "A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer." International Journal of Cancer 139(12): 2646-2654.
dc.identifier.issn0020-7136
dc.identifier.issn1097-0215
dc.identifier.urihttps://hdl.handle.net/2027.42/134414
dc.publisherWiley Periodicals, Inc.
dc.subject.otherestrogen
dc.subject.otherSNPs
dc.subject.othergeneâ environment interactions
dc.subject.otherovarian cancer
dc.subject.otherhormone therapy
dc.titleA splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134414/1/ijc30274_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134414/2/ijc30274.pdf
dc.identifier.doi10.1002/ijc.30274
dc.identifier.sourceInternational Journal of Cancer
dc.identifier.citedreferenceMorch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol 2012; 175: 1234 â 42.
dc.identifier.citedreferenceSprague BL, Trenthamâ Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999â 2010. Obstet Gynecol 2012; 120: 595 â 603.
dc.identifier.citedreferenceCollaborative Group on Epidemiological Studies of Ovarian C, Beral V, Gaitskell K, et al. Menopausal hormone use and ovarian cancer risk: individual participant metaâ analysis of 52 epidemiological studies. Lancet 2015; 385: 1835 â 42.
dc.identifier.citedreferencePearce CL, Chung K, Pike MC, et al. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009; 115: 531 â 9.
dc.identifier.citedreferenceBeral V, Million Women Study C, Bull D, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703 â 10.
dc.identifier.citedreferenceLee AW, Ness RB, Roman LD, et al. Association between menopausal estrogenâ only therapy and ovarian carcinoma risk. Obstet Gynecol 2016; 127: 828 â 36.
dc.identifier.citedreferenceKuchenbaecker KB, Ramus SJ Tyrer J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015; 47: 164 â 71.
dc.identifier.citedreferenceBolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010; 42: 880 â 4.
dc.identifier.citedreferenceGoode EL, Chenevixâ Trench G, Song H, et al. A genomeâ wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010; 42: 874 â 9.
dc.identifier.citedreferencePharoah PD, Tsai YY, Ramus SJ, et al. GWAS metaâ analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013; 45: 362 â 70, 370e361â 2.
dc.identifier.citedreferenceShen H, Fridley BL, Song H, et al. Epigenetic analysis leads to identification of HNF1B as a subtypeâ specific susceptibility gene for ovarian cancer. Nat Commun 2013; 4: 1628.
dc.identifier.citedreferenceSong H, Ramus SJ Tyrer J, et al. A genomeâ wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009; 41: 996 â 1000.
dc.identifier.citedreferencePermuthâ Wey J, Lawrenson K, Shen HC, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 2013; 4: 1627.
dc.identifier.citedreferenceBojesen SE, Pooley KA, Johnatty SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013; 45: 371 â 84, 384e371â 2.
dc.identifier.citedreferencePearce CL, Rossing MA Lee AW, et al. Combined and interactive effects of environmental and GWASâ identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2013; 22: 880 â 90.
dc.identifier.citedreferenceRoyar J, Becher H, Changâ Claude J. Lowâ dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001; 95: 370 â 74.
dc.identifier.citedreferenceBalogun N, Gentryâ Maharaj A, Wozniak EL, et al. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol 2011; 64: 525 â 30.
dc.identifier.citedreferenceLurie G, Terry KL, Wilkens LR, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010; 21: 1731 â 41.
dc.identifier.citedreferenceNess RB, Dodge RC, Edwards RP, et al. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 2011; 21: 188 â 96.
dc.identifier.citedreferenceMoorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008; 167: 1059 â 69.
dc.identifier.citedreferenceWu AH, Pearce CL, Tseng CC, et al. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 2009; 124: 1409 â 15.
dc.identifier.citedreferenceTerry KL, De Vivo I, Titusâ Ernstoff L, et al. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 2005; 65: 5974 â 81.
dc.identifier.citedreferencePike MC, Pearce CL, Peters R, et al. Hormonal factors and the risk of invasive ovarian cancer: a populationâ based caseâ control study. Fertil Steril 2004; 82: 186 â 95.
dc.identifier.citedreferenceBodelon C, Cushingâ Haugen KL, Wicklund KG, et al. Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control 2012; 23: 1985 â 94.
dc.identifier.citedreferenceGlud E, Kjaer SK, Thomsen BL, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004; 164: 2253 â 9.
dc.identifier.citedreferenceBandera EV, King M, Chandran U, et al. Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a populationâ based case control study. BMC Womens Health 2011; 11: 40.
dc.identifier.citedreferenceHowie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda) 2011; 1: 457 â 70.
dc.identifier.citedreferenceGrady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a metaâ analysis. Obstet Gynecol 1995; 85: 304 â 313.
dc.identifier.citedreferenceMorabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1998; 148: 1195 â 1205.
dc.identifier.citedreferencePike MC, Krailo MD, Henderson BE, et al. â Hormonalâ risk factors, â breast tissue ageâ and the ageâ incidence of breast cancer. Nature 1983; 303: 767 â 70.
dc.identifier.citedreferenceSankararaman S, Sridhar S, Kimmel G, et al. Estimating local ancestry in admixed populations. Am J Hum Genet 2008; 82: 290 â 303.
dc.identifier.citedreferenceRothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980; 112: 467 â 70.
dc.identifier.citedreferenceKyo S, Takakura M, Kanaya T, et al. Estrogen activates telomerase. Cancer Res 1999; 59: 5917 â 21.
dc.identifier.citedreferenceKyo S, Takakura M, Kohama T, et al. Telomerase activity in human endometrium. Cancer Res 1997; 57: 610 â 14.
dc.identifier.citedreferenceLiu JP, Li H. Telomerase in the ovary. Reproduction 2010; 140: 215 â 22.
dc.identifier.citedreferenceCalado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009; 114: 2236 â 43.
dc.identifier.citedreferenceMisiti S, Nanni S, Fontemaggi G, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 2000; 20: 3764 â 71.
dc.identifier.citedreferenceKilledar A, Stutz MD, Sobinoff AP, et al. A common cancer riskâ associated allele in the hTERT locus encodes a dominant negative inhibitor of telomerase. PLoS Genet 2015; 11: e1005286
dc.identifier.citedreferenceFranco HL, Dai D, Lee KY, et al. WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. FASEB J 2011; 25: 1176 â 87.
dc.identifier.citedreferenceNyholt DR, Low SK, Anderson CA, et al. Genomeâ wide association metaâ analysis identifies new endometriosis risk loci. Nat Genet 2012; 44: 1355 â 9.
dc.identifier.citedreferencePearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of caseâ control studies. Lancet Oncol 2012; 13: 385 â 94.
dc.identifier.citedreferenceSandini L, Pentti K, Tuppurainen M, et al. Agreement of selfâ reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 2008; 15: 282 â 9.
dc.identifier.citedreferenceGlass R, Johnson B, Vessey M. Accuracy of recall of histories of oral contraceptive use. Br J Prev Soc Med 1974; 28: 273 â 5.
dc.identifier.citedreferenceGentryâ Maharaj A, Taylor H, Kalsi J, et al. Validity of selfâ reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open 2014; 4: e004421
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ijc30274_am.pdf
Size:
348.4KB
Format:
PDF
View/Open
Name:
ijc30274.pdf
Size:
189.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.